Creating a better future with R&D

INTRODUCTION

Equipped with competitive R&D capacity and extensive experience in drug development, inno.N is working to perform further innovative research to create the next generation of healthcare products.

HEAL THE WORLD FOR BETTER LIFE
  • disease-focusDeveloping disease-focused & innovative medicines and biologicals
  • OPEN INNOVATIONAccelerating R&D process and bringing positive outputs by open innovation
  • DISTINGUISHED TECHNOLOGIESBlockbuster generic products and IMD products development
  • PLATFORM TECHNOLOGIESExporting technologies/products globally

inno.N R&D Center is expanding its research focus in accordance with the Center’s current research capabilities and platform technology.
Our vision is to become a global bio-health company that can make a real impact on the world with tangible results. inno.N’s R&D Center continues to invest in more diverse research approaches that align with four main goals to achieve our mission, 'Heal the World for Better Life'.

RESEARCH & DEVELOPMENT OBJECTIVES

DISEASE-FOCUS


Developing disease-focused & innovative medicines and biologicals

OPEN INNOVATION


Accelerating R&D process and bringing positive outputs by open innovation

DISTINGUISHED TECHNOLOGIES


Blockbuster generic products and IMD products development

PLATFORM TECHNOLOGIES


Exporting technologies/products globally

inno.N R&D Center is expanding its research focus in accordance with the Center’s current research capabilities and platform technology.
Our vision is to become a global bio-health company that can make a real impact on the world with tangible results. inno.N’s R&D Center continues to invest in more diverse research approaches that align with four main goals to achieve our mission, ‘Heal the World for Better Life’.

inno.N Corp. Osong Plant

R&D ACHIEVEMENTS

We are on our way to becoming a leading global pharmaceutical company.

  • 2019
    Launched Korea's 30th new drug K-CAB Tab., Launched Exone-R Tab., fixed dose combination for hypertension with dyslipidemia
    Launched Korea's 30th new drug K-CAB Tab.,
    Launched Exone-R Tab., fixed-dose combination for hypertension with dyslipidemia
    • Amlodipine / Valsartan / Rosuvastatin combination drug
  • 2018
    'K-CAB‘Tab.(ingredient name: Tegoprazan), in-house developed new drug for gastroesophageal reflux disease, has received a license from the Ministry of Food and Drug Safety
    'K-CAB‘Tab.(ingredient name: Tegoprazan),
    in-house developed new drug for gastroesophageal reflux disease,
    has received a license from the Ministry of Food and Drug Safety
    • Korea’s No.30 New Drug
  • 2018
    Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to NCPC GeneTech in China
    Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment)
    to NCPC GeneTech in China
  • 2017
    Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to YL Biologics in Japan
    Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment)
    to YL Biologics in Japan
  • 2016
    MACHKHAN
    Launched MACHKHAN, fixed-dose combination IMD for hypertension
    • ARB/CCB combination drug
    • First Candesartan / Amlodipine combination drug
  • 2016
    Won the 17th Korea New Drug Development Award Technology Export Award
    New drug for Gastroesophageal acid reflux K-CAB Tab.(Tegoprazan)
    • P-CAB (Potassium -Competitive Acid Blocker) New Drug
    • Technology export to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China (2015)
    • New Drug Application (2017)
  • 2014
    VOGMET
    Launched VOGMET, fixed-dose combination IMD for Diabetes
    • α-glucosidase/biguanides combination drug
    • First Voglibose/Metformin combination drug
  • 2013
    EXONE
    Launched EXONE, combination drug for hypertension
    • ARB/CCB combination drug
    • Valsartan / Amlodipine combination drug
    • Excellent optical (light) stability with differentiated technology
  • 2012
    Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
    Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
    • Accredited in Excellence in new drug R & D capability and overseas expansion capability
  • 1998
    EPOKINE
    Launched EPOKINE, renal anemia treatment
    • Developed the first EPO(erythropoietin) in Korea and the third in the world
  • 1995
    CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
    CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
    • Used the first in-vivo substance, TOF, in Korea
  • 1992
    CONDITION
    Launched CONDITION, a nationwide anti hangover drink
    • The first anti-hangover drink in Korea
  • 1986
    HEPACCINE-B
    Launched HEPACCINE-B, Hepatitis B vaccine
    • first-developed in Korea
    • World's 2nd hepatitis B vaccine HEPACCINE-B, obtained WHO certification (1993)